Tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows

· Medical Xpress

by PNAS Nexus

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Weight-loss response groups defined by maximum weight loss in a two-year follow up period. Credit: Venkatakrishnan et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and colleagues explored the full range of responses to tirzepatide (e.g., Mounjaro or Zepbound) and semaglutide (e.g., Ozempic, Wegovy or Rybelsus) by analyzing de-identified electronic health records for matched cohorts of 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients. In the real world, outcomes ranged from minimal weight loss to more than a 25% reduction in body weight.

Patients taking tirzepatide lost more weight than those taking semaglutide (mean reduction, 14.7% vs. 10.8% of body weight). The tirzepatide group had nearly twice as many "high responders," defined as people who lost more than 15% of their body weight in a year, as the semaglutide group. Tirzepatide patients also had fewer gastrointestinal, headache and fatigue adverse events than semaglutide patients.

Female and white patients taking either drug more frequently achieved significant weight loss than male, Black and Hispanic patients, who were more likely to lose less than 5% of their body weight in a year. According to the authors, the reasons for these demographic patterns are unknown and should be investigated.

The authors published their work in PNAS Nexus.

Distribution of tirzepatide- vs. semaglutide-treated patients by weight-loss response group. Credit: Venkatakrishnan et al.

Publication details

Weight-loss dynamics with tirzepatide versus semaglutide, PNAS Nexus (2026). doi.org/10.1093/pnasnexus/pgag171

Journal information: PNAS Nexus

Key medical concepts

SemaglutideTirzepatideGLP-1 Receptor Agonist [EPC]

Clinical categories

EndocrinologyWeight managementClinical pharmacology Provided by PNAS Nexus Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows (2026, June 16) retrieved 16 June 2026 from https://medicalxpress.com/news/2026-06-tirzepatide-outperformed-semaglutide-weight-loss.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.